OBJECTIVES: The goal of this study was to test the hypothesis that growth hormone (GH) administration to patients with chronic heart failure (CHF) corrects their vascular dysfunction. BACKGROUND:Endothelial dysfunction is a prominent feature of CHF. Recent evidence indicates that GH plays a role in vascular reactivity. METHODS: We studied vascular reactivity in 16 patients with CHF (New York Heart Association class II to III) before and after three months of GH (4 IU subcutaneously every other day) or placebo administration in a randomized, double-blind trial. We measured forearm blood flow (FBF) by strain-gauge plethysmography during intrabrachial, graded infusion of acetylcholine (ACh) and sodium nitroprusside (NP). We also measured the forearm balance of nitrite and cyclic guanosine monophosphate (cGMP) before and during ACh infusion. Maximal oxygen uptake (VO2max) was measured by breath-to-breath respiratory gas analysis. RESULTS: Before treatment, the response of FBF to ACh was flat (p = NS). Growth hormone, but not placebo, greatly improved this response (p = 0.03) and, concomitantly, increased the forearm release of nitrite and cGMP (p < 0.05). Growth hormone also potentiated the FBF response to NP (p = 0.013). Growth hormone interacted with ACh response (p = 0.01) but not with the response to NP (p = NS). Accordingly, GH enhanced the slope of the dose-response curve to ACh (p < 0.05) but not to NP. The VO2max increased significantly after GH treatment (20 +/- 2 and 26 +/- 2 ml x Kg(-1) x min(-1) before and after GH treatment, respectively, p < 0.05) but not after placebo. CONCLUSIONS: A three-month treatment with GH corrected endothelial dysfunction and improved non-endothelium-dependent vasodilation in patients with CHF. The data highlight the potential role of GH in the progression of congestive heart failure.
RCT Entities:
OBJECTIVES: The goal of this study was to test the hypothesis that growth hormone (GH) administration to patients with chronic heart failure (CHF) corrects their vascular dysfunction. BACKGROUND:Endothelial dysfunction is a prominent feature of CHF. Recent evidence indicates that GH plays a role in vascular reactivity. METHODS: We studied vascular reactivity in 16 patients with CHF (New York Heart Association class II to III) before and after three months of GH (4 IU subcutaneously every other day) or placebo administration in a randomized, double-blind trial. We measured forearm blood flow (FBF) by strain-gauge plethysmography during intrabrachial, graded infusion of acetylcholine (ACh) and sodium nitroprusside (NP). We also measured the forearm balance of nitrite and cyclic guanosine monophosphate (cGMP) before and during ACh infusion. Maximal oxygen uptake (VO2max) was measured by breath-to-breath respiratory gas analysis. RESULTS: Before treatment, the response of FBF to ACh was flat (p = NS). Growth hormone, but not placebo, greatly improved this response (p = 0.03) and, concomitantly, increased the forearm release of nitrite and cGMP (p < 0.05). Growth hormone also potentiated the FBF response to NP (p = 0.013). Growth hormone interacted with ACh response (p = 0.01) but not with the response to NP (p = NS). Accordingly, GH enhanced the slope of the dose-response curve to ACh (p < 0.05) but not to NP. The VO2max increased significantly after GH treatment (20 +/- 2 and 26 +/- 2 ml x Kg(-1) x min(-1) before and after GH treatment, respectively, p < 0.05) but not after placebo. CONCLUSIONS: A three-month treatment with GH corrected endothelial dysfunction and improved non-endothelium-dependent vasodilation in patients with CHF. The data highlight the potential role of GH in the progression of congestive heart failure.
Authors: Carmen Gonzalez; Hector Rosas-Hernandez; Brenda Jurado-Manzano; Manuel Alejandro Ramirez-Lee; Samuel Salazar-Garcia; Pedro Pablo Martinez-Cuevas; Aída Jimena Velarde-Salcedo; Humberto Morales-Loredo; Ricardo Espinosa-Tanguma; Syed F Ali; Rafael Rubio Journal: Acta Pharmacol Sin Date: 2015-04-20 Impact factor: 6.150
Authors: Anna Csiszar; Nazar Labinskyy; Viviana Perez; Fabio A Recchia; Andrej Podlutsky; Partha Mukhopadhyay; Gyorgy Losonczy; Pal Pacher; Steven N Austad; Andrzej Bartke; Zoltan Ungvari Journal: Am J Physiol Heart Circ Physiol Date: 2008-08-29 Impact factor: 4.733
Authors: Guolian Li; Juan-Pablo Del Rincon; Linda A Jahn; Yangsong Wu; Bruce Gaylinn; Michael O Thorner; Zhenqi Liu Journal: J Clin Endocrinol Metab Date: 2008-01-08 Impact factor: 5.958
Authors: Michele Arcopinto; Andrea Salzano; Francesco Giallauria; Eduardo Bossone; Jörgen Isgaard; Alberto M Marra; Emanuele Bobbio; Olga Vriz; David N Åberg; Daniele Masarone; Amato De Paulis; Lavinia Saldamarco; Carlo Vigorito; Pietro Formisano; Massimo Niola; Francesco Perticone; Domenico Bonaduce; Luigi Saccà; Annamaria Colao; Antonio Cittadini Journal: PLoS One Date: 2017-01-17 Impact factor: 3.240
Authors: Nina A Mikirova; James A Jackson; Ron Hunninghake; Julian Kenyon; Kyle W H Chan; Cathy A Swindlehurst; Boris Minev; Amit N Patel; Michael P Murphy; Leonard Smith; Doru T Alexandrescu; Thomas E Ichim; Neil H Riordan Journal: J Transl Med Date: 2009-12-15 Impact factor: 5.531
Authors: Francesco Angelini; Francesca Pagano; Antonella Bordin; Vittorio Picchio; Elena De Falco; Isotta Chimenti Journal: Front Cardiovasc Med Date: 2017-10-06